Kymab CTO Professor Allan Bradley to present at Canaccord Genuity Annual Growth Conference on August 10, 2017
Kymab, an emerging biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs, announces that Chief Technical Officer, Professor Allan Bradley, has been invited to present at the Canaccord Genuity 37th Annual Growth Conference in Boston, MA.
Professor Bradley is scheduled to present on Thursday August 10, at 3.30 pm (ET). Professor Bradley will overview Kymab’s successful track record in drug discovery and development and focus on its pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity; haematology and infectious disease.
Notes to Editors
Published at Cambridge, UK, 29 July 2017
About Professor Allan Bradley
Read about Allan Bradley's path to Kymab
Professor Allan Bradley FRS is Kymab's Chief Technical Officer and co-founder.
Professor Bradley is a geneticist who has made fundamental contributions to our understanding of embryonic stem (ES) cells and DNA manipulation. His techniques used to generate mice containing specific gene mutations contributed to the 2007 Nobel Prize in Physiology or Medicine.
Professor Bradley was Director of the Wellcome Trust Sanger Institute in Cambridge, UK, from 2000 to 2010. During this time, he established a new direction for the Institute and initiated the largest gene knockout project ever attempted on ES cells. He also founded Kymab, the Institute’s first spin-out company.
He received the DeBakey Award of Baylor College of Medicine Texas, USA in 1994 for his work on chromosome engineering in ES cells and elected Fellow of the Royal Society in July 2002.
He is the author of almost 300 scientific articles and book chapters.
Professor Bradley has been active in commercialising technology from his laboratory by founding several companies, including a publicly traded US genomics company, Lexicon Genetics Inc.
Kymab is an emerging biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains the entire repertoire of human antibodies, making it the most comprehensive antibody development platform available.
Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing which includes US$100m Series C financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity, haematology, infectious disease and other areas.
For more information please see http://www.kymab.com
Kymab is a trademark of Kymab Limited.